HPV vaccination and early declines in cervical cancer deaths
Menée en Angleterre à partir de données 2001-2024, cette étude analyse l'évolution de la mortalité par cancer du col de l'utérus et estime l'impact, sur le nombre de décès liés à ce cancer, du programme national de vaccination contre le papillomavirus humain
Public health has been waiting two decades1,2 for signs that human papillomavirus (HPV) vaccination prevents deaths, not only precancerous lesions and cancer. Studies in countries where HPV vaccination was introduced early have shown substantial decreases in cervical cancer incidence, reporting 84–88% reductions in vaccinated compared with unvaccinated women in studies in Sweden, Denmark, and England.3–5 Now, the impact of HPV vaccination on cervical cancer mortality is emerging,6,7 supported by mortality data from England in a new study in The Lancet by Peter Sasieni and Milena Falcaro,8 which is among the first national-level analyses of cervical cancer mortality following HPV vaccination introduction.
The Lancet , commentaire, 2026